We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

March 10, 2022

A Round-up of 5 Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community

This past month, 109 of our HealthXL community members met across 12 meetings to discuss digital measures in clinical trials, clinical and economic outcomes for RPM and DTx last mile delivery, among other topics. We’ve put together a snapshot of 5 expert insights from these meetings.


#1 On the role of digital tech for trial recruitment and retention: Issues with recruitment and retention of clinical trial participants are obvious in numbers. Digital tools can be useful on many occasions, some examples: to enroll patients from different geographies, improve patient awareness on clinical trials they can participate in, reduce the burden of participating in a clinical trial, reduce biases from a health equity perspective, reach a greater number of patients for large studies, etc. Digital solutions can also help across the ecosystem of clinical trials. When talking to pharma, they are more open to digital tools for recruitment and retention compared to other areas like digital biomarkers. However, they are still risk averse, which is a huge barrier. There is less resistance from pharma when the digital tech component doesn’t lead to big changes in their protocols. 


#2 On digital health solutions for cancer patients: Patient support is key to improve Quality of Life (QoL). Aside from the disease itself, oncology patients deal with mental health issues and side effects that compromise their QoL. Digital health solutions are working to tackle these pain points, however, solutions truly focused on QoL and those that help care teams better manage their patients are still lacking. 



#3 On DTx and Pharma partnerships: Before a DTx company approaches pharma, they need to understand the specific pharma company they want to work with, their needs and their roadmap. This is important because there may be a fit now, but not in the future plan. We are still in the early days and pharma companies are experimenting with different business models. At the end of the day, there needs to be a strategic fit with the patient pain points pharma has identified. DTx solutions will be relevant for pharma companies if they: 


#4 On common misconceptions about SaMD regulation in the US: Three common misconceptions about SaMD regulation in the US include: 


Misconception: New guidance(s) dramatically deviate from established regulatory principles and practices. 

Truth: Generally, most new guidance presents processes and interpretation consistent with established frameworks. 


Misconception: Hardware is easily separated from software.

Truth: Any hardware customization to support device use (e.g. customer sensors, configurations, processors, etc.) prevent a product from being SaMD. 


Misconception: New programs/guidance creates significant reduction in Time-to-Market (TTM) for SaMD devices. 

Truth: Available data shows TTM for most types of submissions remains relatively stable. 


#5 On clinical and economic outcomes for RPM: We have seen some convincing studies showing that by using something as simple as ePROs, we can actually improve clinical outcomes. As generating the evidence from RPM tools can take a lot of time and resources, there are many RPM companies referring to those studies when talking about their clinical evidence. In terms of economic outcomes, only by keeping patients on their pills will RPM programs save money for health systems and pharma conducting RCTs. A lot of payers and health systems think about reducing costs in the short term, hence, if companies can’t prove savings in the short term, it will be harder to get buy-in. 


Want to join the conversation? Check out our website for upcoming meetings and events. 

Interested in more expert insights and takeaways? Become a member of our HealthXL Community for access to polls and summaries from all of our meetings.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

No upcoming Virtual Events scheduled. Please check back again soon.

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

16TH APRIL 2024 @ 11AM ET

Big Tech and Pharma: Will they, won't they?

As Big Tech seeks to expand their footprint in the health industry, the dynamics of their relationship with Pharma are under scrutiny.

Sophie Ghazal
Featuring
Sophie Ghazal
Global Digital Solutions and Strategic Alliances, Merck
18th April 2024 @ 11am ET

BYOD: What's your Wearable of Choice?

Wearables, like smartwatches and fitness trackers, have transformed patient health monitoring, providing real-time data for personalised care.

Ralph Morales III
Featuring
Ralph Morales III
Director, Healthcare Innovation, Oura
23RD APRIL 2024 @ 11AM ET

Masterclass: Digital Health Regulatory Updates

The digital health industry is revolutionising healthcare delivery, but navigating the ever-changing regulatory landscape can be daunting.

Piotr Sokolowski
Featuring
Piotr Sokolowski
Head of Strategy, MedTech Solutions at S3 Connected Health

HealthXL Insider Boston

Join HealthXL on the 23rd of April in Boston as we discuss the History of Digital Health: Learning from our Mistakes to Succeed in 2024.
Featuring

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.